Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
5
×
biotech
boston blog main
boston top stories
5
×
life sciences
national blog main
national top stories
new york blog main
new york top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
fda
novartis
alder biopharmaceuticals
alirocumab
alnylam pharmaceuticals
calcitonin gene-related peptide
eli lilly
eptinezumab
erenumab
evolocumab
fremanezumab
What
drug
new
5
×
fda
approval
brings
cholesterol
class
drugs
medicines
migraine
wave
won
acquire
advantages
agreed
amgen
arguments
bar
big
billion
bio
candidates
cash
commercialized
companies
company
competitors
compound
deal
decades
developed
expect
expensive
faces
financial
foe
gamble
gets
head
healthcare
Language
unset
Current search:
new
×
" boston top stories "
×
amgen
×
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines